CL2017001231A1 - Espiro-tiazolonas - Google Patents

Espiro-tiazolonas

Info

Publication number
CL2017001231A1
CL2017001231A1 CL2017001231A CL2017001231A CL2017001231A1 CL 2017001231 A1 CL2017001231 A1 CL 2017001231A1 CL 2017001231 A CL2017001231 A CL 2017001231A CL 2017001231 A CL2017001231 A CL 2017001231A CL 2017001231 A1 CL2017001231 A1 CL 2017001231A1
Authority
CL
Chile
Prior art keywords
thiazolones
receiver
act
disorders
spiro
Prior art date
Application number
CL2017001231A
Other languages
English (en)
Inventor
Cosimo Dolente
Bernhard Fasching
Schmitt Valerie Runtz
Patrick Schnider
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2017001231A1 publication Critical patent/CL2017001231A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN PROPORCIONA ESPIRO-TIAZOLONAS, QUE ACTÚAN COMO MODULADORES DEL RECEPTOR V1a, Y EN PARTICULAR, COMO ANTAGONISTAS DEL RECEPTOR V1a, SU FABRICACIÓN, A COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y A SU USO COMO MEDICAMENTOS. LOS PRESENTES COMPUESTOS SON ÚTILES COMO AGENTES TERAPÉUTICOS QUE ACTÚAN DE MANERA PERIFÉRICA Y CENTRAL EN CONDICIONES DE SECRECIÓN INADECUADA DE VASOPRESINA, ANSIEDAD, TRASTORNOS DEPRESIVOS, TRASTORNO OBSESIVO-COMPULSIVO, TRASTORNOS DEL ESPECTRO AUTISTA, ESQUIZOFRENIA,  COMPORTAMIENTO AGRESIVO Y TRASTORNOS DEL SUEÑO POR CAMBIO DE FASE, EN PARTICULAR DESCOMPENSACIÓN HORARIA.</p>
CL2017001231A 2014-11-14 2017-05-12 Espiro-tiazolonas CL2017001231A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14193294 2014-11-14

Publications (1)

Publication Number Publication Date
CL2017001231A1 true CL2017001231A1 (es) 2018-01-12

Family

ID=51904773

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001231A CL2017001231A1 (es) 2014-11-14 2017-05-12 Espiro-tiazolonas

Country Status (21)

Country Link
US (1) US10092551B2 (es)
EP (1) EP3218381B1 (es)
JP (1) JP6629855B2 (es)
KR (1) KR20170084047A (es)
CN (1) CN107001382B (es)
AR (1) AR102633A1 (es)
AU (1) AU2015345102A1 (es)
BR (1) BR112017007363A2 (es)
CA (1) CA2963188A1 (es)
CL (1) CL2017001231A1 (es)
CO (1) CO2017002963A2 (es)
CR (1) CR20170195A (es)
EA (1) EA201790919A1 (es)
IL (1) IL250999A0 (es)
MX (1) MX2017006294A (es)
PE (1) PE20170671A1 (es)
PH (1) PH12017500891A1 (es)
SG (1) SG11201703604VA (es)
TW (1) TW201625642A (es)
WO (1) WO2016075181A1 (es)
ZA (1) ZA201701914B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2608718A1 (en) * 2005-05-18 2006-11-23 Pfizer Limited 1, 2, 4-triazole derivatives as vasopressin antagonists
DE602007006990D1 (de) * 2006-12-07 2010-07-15 Hoffmann La Roche Spiropiperidinderivate als antagonisten des via-rezeptors
CN101583615B (zh) * 2007-01-12 2012-07-04 弗·哈夫曼-拉罗切有限公司 螺哌啶甘氨酰胺衍生物
PT2356123E (pt) * 2008-11-13 2012-10-31 Hoffmann La Roche Espiro-5,6-di-hidro-4h-2,3,5,10b-tetra-azabenzo[ e]azulenos
CN105263910A (zh) * 2013-02-18 2016-01-20 斯克利普斯研究所 具有治疗潜力的血管加压素受体调节剂

Also Published As

Publication number Publication date
WO2016075181A1 (en) 2016-05-19
MX2017006294A (es) 2017-08-21
JP6629855B2 (ja) 2020-01-15
CR20170195A (es) 2017-05-31
JP2017533933A (ja) 2017-11-16
KR20170084047A (ko) 2017-07-19
CN107001382A (zh) 2017-08-01
TW201625642A (zh) 2016-07-16
EA201790919A1 (ru) 2017-08-31
AR102633A1 (es) 2017-03-15
PH12017500891A1 (en) 2017-11-06
US20170246153A1 (en) 2017-08-31
CN107001382B (zh) 2019-10-25
US10092551B2 (en) 2018-10-09
ZA201701914B (en) 2018-12-19
IL250999A0 (en) 2017-04-30
PE20170671A1 (es) 2017-05-22
SG11201703604VA (en) 2017-06-29
CO2017002963A2 (es) 2017-07-19
BR112017007363A2 (pt) 2017-12-19
AU2015345102A1 (en) 2017-03-30
EP3218381A1 (en) 2017-09-20
CA2963188A1 (en) 2016-05-19
EP3218381B1 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CL2015002125A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
CL2016001983A1 (es) Compuestos aza bicíclicos como agonistas del receptor muscarínico m1 y/o m4
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
MX2018006217A (es) Agonistas del receptor de apelina y metodos de uso.
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
MX2017014375A (es) Moduladores del ccr2.
MX2016010216A (es) Composiciones farmaceuticas solidas de antagonistas de los receptores de androgenos.
HUE053943T2 (hu) Azabenzimidazolok és ampa receptor modulátorokként való alkalmazásuk
CL2016002569A1 (es) Anticuerpos, composiciones farmacéuticas y usos de los mismos
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
CR20160374A (es) Ciclopentanos sustituidos en 1,2 como antagonistas del receptor de orexina
CL2016002615A1 (es) Heterociclil-sulfonas sustituidas con heteroarilo y su uso contra el dolor, accidente cerebrovascular, transtornos anímicos, epilepsia, esquizofrenia y trastornos neurodegenerativos.
MX2016015630A (es) Nuevos compuestos.
MX378108B (es) Anticuerpos anti-met y composiciones.
MX2017007371A (es) Compuestos antibacterianos que tienen un amplio espectro de actividad.
CL2016002240A1 (es) Derivados de piperidina como antagonista de receptores de orexina
DOP2016000311A (es) Nuevos compuestos
ECSP16082599A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1
CL2016002085A1 (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina.
CL2019000027A1 (es) Regímenes de dosificación de antagonistas de la lingo-1 y usos para el tratamiento de los trastornos desmielinizantes.
MX2017009608A (es) Compuestos anticancerigenos.